Neil Vasan: 4 FDA-Approved Drugs in Breast Cancer in 2025

Neil Vasan, Director of Breast Cancer Translational Research at NYU Langone Health, shared a post on X:

“Four drugs FDA-approved in BC in 2025.

1. TDxD + P – Approved for 1L HER2+ MBC based on DESTINY-Breast09.
2. Imlunestrant – Approved for ER+ MBC with ESR1 mutations based on EMBER-3.
3. Dato-DxD – Approved for ER+ MBC based on TROPION-Breast02.
5. Pertuzumab biosimilar (Poherdy) – Approved based on analytical and clinical equivalence studies.”

More posts featuring Neil Vasan.